The Importance of MRD in Non-Acute Promolocytic Leukemia

Most of the data we have on MRD is in the context of intensive chemotherapy not for all patients who are getting HMA. In AML, we have two main methods, either fluocytometry or next-gen sequencing. There are a number of issues with standardization and what is the cut-off that you have to use in terms of how do you measure these assays. And someone who has gone into remission, make sure they are negative. If it shows up in the blood, it's likely that the patient who relaps very quickly after that.